Single-dose rasburicase might be adequate to overcome tumor lysis syndrome in hematological malignancies

Introduction: Tumor lysis syndrome (TLS) is a commonly observed oncological emergency that requires prompt diagnosis and treatment. Rasburicase is a recombinant urate oxidase endorsed in TLS for the treatment of hyperuricemia. The effect of single-dose 7.5 mg rasburicase at longer follow-ups was not widely investigated.Patients and Methods: Eighty-two patients included in the study with clinical TLS and laboratory TLS. The primary endpoint was the normalization of uric acid (

Source: Clinical Lymphoma, Myeloma and Leukemia - August 28, 2021 Category: Hematology Authors: Samet Yaman, Semih Ba şcı, Gökhan Turan, Bahar Uncu Ulu, Tuğçe Nur Yiğenoğlu, Mehmet Sinan Dal, Merih Kızıl Çakar, Fevzi Altuntaş Source Type: research